Ibudilast in the Treatment of Patients With Chronic Migraine.

Migraine Headache Clinical Trial

— IBU-003  

Official title:

Targeting Glial Inhibition to Attenuate Chronic Migraine: AN INTERNATIONAL DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED TRIAL OF IBUDILAST

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01389193
• Other study ID #: IBU-003
• Secondary ID: MRF and DRC
• Status: Completed
• Phase: Phase 1
• First received: June 29, 2011
• Last updated: December 28, 2015
• Start date: June 2013
• Est. completion date: December 2015

Study information

• Verified date: December 2015
• Source: Aalborg University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Australia: Human Research Ethics CommitteeThe Human Research Ethics Committee of the Royal Adelaide Hospital: Australia
• Study type: Interventional

Clinical Trial Summary

This will be a double-blind, randomised, placebo-controlled, two period cross over study of ibudilast in the treatment of chronic migraine.

For participants resident in Adelaide, South Australia (i.e. "local participants"):

The study will involve a screening visit followed by eight visits to the Pain and Anaesthesia Research Clinic (PARC), within the Royal Adelaide Hospital (RAH), for baseline testing, initiation of the study medications and ongoing data collection (one baseline and three study visits during each treatment period).

At the baseline visit, blood samples to assess biomarkers (glutamate, calcitonin gene-related peptide, glial fibrillary acidic protein and S100β) will be taken. Patients will then be randomised (in a 1:1 ratio) to commence either ibudilast or placebo treatment, which will continue for 8 weeks. Subsequently participants will undergo a 4-week washout period. At the end of the washout period a second 8-week treatment block with the alternative treatment will commence.

Patients will complete a headache diary daily for at least 4 weeks prior to the baseline visit, throughout the treatment and washout periods and for 4 weeks after treatment ceases. The diary will record headache frequency, duration, intensity, pain characteristics and medication intake for comparison with baseline data.

From screening until the final study visit (over a minimum of 6 months) a total of approximately 200 mL in blood samples will be taken from each local participant.

For participants located in country or interstate locations:

The same study will be undertaken, but instead of attending the Pain and Anaesthesia Research Clinic (PARC), within the Royal Adelaide Hospital (RAH) for screening and study visits, these will be managed remotely through:

basic input from the participant's GP during the screening period correspondence with the PI and study staff via registered post, phone or Skype scheduled visits to the nearest pathology collection centre for blood biochemistry and haematology analysis

Interstate or country participants will also be exempt from collection of blood samples for biomarker analysis, hence a total of approximately 120 mL of blood samples will be taken from each interstate or country participant.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 33
• Est. completion date: December 2015
• Est. primary completion date: December 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

Men and women aged between 18 to 65 years Migraine with or without aura, as diagnosed according to the second edition International Classification of Headache Disorders (ICHD-II) Onset of migraine before 50 years of age Headache on 15 or more days per month Migraine-like headache on 8 or more days per month, as per the IHS guidelines

Exclusion Criteria:

• Change in type or dose of migraine prophylactic medication in last 3 months

• Medication overuse headache as diagnosed according to the ICHD-IIR

• Post-traumatic headache as diagnosed according to the ICHD-II

• Other dominant chronic pain condition

• Known active inflammatory diseases such as rheumatoid arthritis

• History of recent cerebrovascular disorder

• Unable to provide written informed consent

• Unable to read and write in English

• Severe psychological/psychiatric disorders

• Recent history of significant trauma, as determined by the Principal Investigator including major surgery within the previous 2 months or major surgery planned during the treatment period

• Recent history of drug or alcohol abuse

• Any clinically significant findings on screening blood sample results

• Current malignancy

• Known hypersensitivity to ibudilast or excipients in Ketas® formulation

• Renal or hepatic impairment, defined as baseline GFR (as calculated by the Cockcroft-Gault equation) of <60 mL/min, LFTs (excluding bilirubin) > 3 times the upper limit of normal or bilirubin > 2 times the upper limit of normal

• For females of childbearing potential:

• Pregnancy

• Lack of adequate contraception (abstinence, double barrier method, intrauterine device, surgical sterilization (self or partner), hormonal contraceptive methods (oral, injected, or implanted)

• Breastfeeding

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Migraine Disorders
• Migraine Headache

Intervention

Drug:
• Ibudilast
Ibudilast 40 mg twice daily oral capsules for a duration of 8 weeks
• Placebo
Placebo 40 mg twice daily oral capsules for a duration of 8 weeks

Locations

Country	Name	City	State
Australia	School of Medical sciences, University of Adelaide	Adelaide

Sponsors (3)

Lead Sponsor	Collaborator
Parisa Gazerani	Migraine Research Foundation, The Ministry of Science, Technology and Innovation, Denmark

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	safety and tolerability of ibudilast	Ibudilast 40 mg or placebo twice daily for 8 weeks is effective and safe in a chronic migraine population.	8 weeks	Yes
Primary	Primary efficacy end point	As suggested by the IHS guidelines for clinical trials in chronic migraine, the primary efficacy endpoint will be number of headache days per month with moderate or severe intensity. Study outcomes will be assessed at baseline and at weeks 2, 4 and 8 of each treatment period.; To monitor treatment with ibudilast, blood biochemistry (including assessment of renal and hepatic including GGT function) and haematology will be assessed at baseline, and at weeks 2, 4 and 8 of each treatment period. Patients will also be screened for adverse effects via questionnaire at each visit during treatment.	8 weeks	Yes
Secondary	Secondary efficacy end points	The secondary end points assessed will include: Migraine frequency (number of days with migraine of any severity/month); Migraine episode frequency (number of migraine episodes/month); Medication frequency (number of days acute headache medication taken/month); Headache related impact on quality of life as assessed using the HIT-6; Cutaneous allodynia as assessed using the ASC-12; Biomarker levels	8 weeks	Yes
Secondary	Serum biomarker levels	To determine if serum levels of the following potential biomarkers are able to differentiate response to treatment with ibudilast: glutamate, calcitonin gene-related peptide, glial fibrillary acidic protein and S100 calcium binding protein ß.	8 weeks	No